Sentiment-Signal
4,9
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (29.04.2026)
HOCH Abgang Schlüsselpersonen (29.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 29.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 05.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; A |
| 05.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; A |
Stammdaten
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | VERTEX PHARMACEUTICALS INC / MA |
|---|---|
| Ticker | VRTX |
| CIK | 0000875320 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 107,99 Mrd. USD |
| Beta | 0,37 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 12,001,300,000 | 3,953,200,000 | 15.32 | 25,643,000,000 | 18,665,800,000 |
| 2025-09-30 | 10-Q | 3,076,400,000 | 1,082,900,000 | 4.20 | 24,862,300,000 | 17,318,800,000 |
| 2025-06-30 | 10-Q | 2,964,700,000 | 1,032,900,000 | 3.99 | 24,036,700,000 | 17,175,400,000 |
| 2025-03-31 | 10-Q | 2,770,200,000 | 646,300,000 | 2.49 | 22,880,500,000 | 16,496,300,000 |
| 2024-12-31 | 10-K | 11,020,100,000 | -535,600,000 | -2.08 | 22,533,200,000 | 16,409,600,000 |
| 2024-09-30 | 10-Q | 2,771,900,000 | 1,045,400,000 | 4.01 | 22,240,200,000 | 15,630,900,000 |
| 2024-06-30 | 10-Q | 2,645,600,000 | -3,593,600,000 | -13.92 | 20,132,100,000 | 14,774,700,000 |
| 2024-03-31 | 10-Q | 2,690,600,000 | 1,099,600,000 | 4.21 | 23,917,400,000 | 18,546,600,000 |
| 2023-12-31 | 10-K | 9,869,200,000 | 3,619,600,000 | 13.89 | 22,730,200,000 | 17,580,400,000 |
| 2023-09-30 | 10-Q | 2,483,500,000 | 1,035,300,000 | 3.97 | 21,726,200,000 | 16,512,800,000 |
| 2023-06-30 | 10-Q | 2,493,200,000 | 915,700,000 | 3.52 | 20,349,200,000 | 15,470,200,000 |
| 2023-03-31 | 10-Q | 2,374,800,000 | 699,800,000 | 2.69 | 18,974,200,000 | 14,432,300,000 |
| 2022-12-31 | 10-K | 8,930,700,000 | 3,322,000,000 | 12.82 | 18,150,900,000 | 13,912,700,000 |
| 2022-09-30 | 10-Q | 2,334,300,000 | 930,500,000 | 3.59 | 16,706,400,000 | 13,029,600,000 |
| 2022-06-30 | 10-Q | 2,196,200,000 | 810,500,000 | 3.13 | 15,582,200,000 | 11,933,500,000 |
| 2022-03-31 | 10-Q | 2,097,500,000 | 762,100,000 | 2.96 | 14,256,100,000 | 10,907,000,000 |
| 2021-12-31 | 10-K | 7,574,400,000 | 2,342,100,000 | 9.01 | 13,432,500,000 | 10,100,000,000 |
| 2021-09-30 | 10-Q | 1,984,100,000 | 851,900,000 | 3.28 | 12,618,745,000 | 9,530,800,000 |
| 2021-06-30 | 10-Q | 1,793,400,000 | 67,000,000 | 0.26 | 12,221,686,000 | 9,196,400,000 |
| 2021-03-31 | 10-Q | 1,724,300,000 | 653,100,000 | 2.49 | 12,115,059,000 | 8,980,300,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -978 | 449.17 | -439,288.26 | -24,9% | |
| 2026-03-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2,329 | 450.95 | -1,050,262.55 | -59,5% | |
| 2026-03-13 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2,329 | 481.79 | -1,122,088.91 | -63,6% | |
| 2026-03-11 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,633 | 498.42 | -1,312,339.86 | -74,4% | |
| 2026-03-04 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,437 | 475.30 | -1,158,306.10 | -65,6% | |
| 2026-03-02 | Liu Joy | Officer, EVP and Chief Legal Officer | Open Market Sale | -892 | 495.96 | -442,396.32 | -25,1% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2,725 | 490.54 | -1,336,721.50 | -75,7% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2,520 | 493.29 | -1,243,090.80 | -70,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -2,510 | 487.13 | -1,222,696.30 | -69,3% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -1,725 | 496.95 | -857,238.75 | -48,6% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -949 | 491.30 | -466,243.70 | -26,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -460 | 489.32 | -225,087.20 | -12,8% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -400 | 479.75 | -191,900.00 | -10,9% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -240 | 482.84 | -115,881.60 | -6,6% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -120 | 481.50 | -57,780.00 | -3,3% | |
| 2026-02-27 | Bozic Carmen | Officer, EVP and CMO | Open Market Sale | -2,329 | 480.31 | -1,118,641.99 | -63,4% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -15,580 | 495.38 | -7,718,020.40 | -437,3% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -5,995 | 496.16 | -2,974,479.20 | -168,5% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3,498 | 494.33 | -1,729,166.34 | -98,0% | |
| 2026-02-27 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Sale | -3,278 | 488.27 | -1,600,549.06 | -90,7% | |
| 2026-02-26 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -357 | 483.36 | -172,559.52 | -9,8% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,410 | 489.00 | -1,178,490.00 | -66,8% | |
| 2026-02-25 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1,846 | 486.35 | -897,802.10 | -50,9% | |
| 2026-02-25 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -668 | 486.35 | -324,881.80 | -18,4% | |
| 2026-02-25 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -223 | 486.35 | -108,456.05 | -6,1% | |
| 2026-02-25 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -945 | 486.35 | -459,600.75 | -26,0% | |
| 2026-02-25 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -620 | 486.35 | -301,537.00 | -17,1% | |
| 2026-02-25 | McKechnie Duncan | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,500 | 486.35 | -1,215,875.00 | -68,9% | |
| 2026-02-25 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -260 | 486.35 | -126,451.00 | -7,2% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -1,848 | 465.80 | -860,798.40 | -48,8% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -19,662 | 468.57 | -9,213,023.34 | -522,0% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -11,712 | 470.54 | -5,510,964.48 | -312,3% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -10,263 | 467.75 | -4,800,518.25 | -272,0% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -7,241 | 469.61 | -3,400,446.01 | -192,7% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -4,237 | 471.43 | -1,997,448.91 | -113,2% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -2,730 | 465.05 | -1,269,586.50 | -71,9% | |
| 2026-02-19 | Sachdev Amit | Officer, EVP Chief Patient & Ext Af Off | Open Market Sale | -920 | 463.91 | -426,797.20 | -24,2% | |
| 2026-02-18 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1,244 | 473.68 | -589,257.92 | -33,4% | |
| 2026-02-18 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -1,182 | 473.68 | -559,889.76 | -31,7% | |
| 2026-02-18 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -638 | 473.68 | -302,207.84 | -17,1% | |
| 2026-02-18 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -368 | 473.68 | -174,314.24 | -9,9% | |
| 2026-02-18 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -817 | 473.68 | -386,996.56 | -21,9% | |
| 2026-02-17 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -2,476 | 489.46 | -1,211,902.96 | -68,7% | |
| 2026-02-17 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2,437 | 489.46 | -1,192,814.02 | -67,6% | |
| 2026-02-17 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1,557 | 489.46 | -762,089.22 | -43,2% | |
| 2026-02-17 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -609 | 489.46 | -298,081.14 | -16,9% | |
| 2026-02-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2,031 | 489.46 | -994,093.26 | -56,3% | |
| 2026-02-13 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 500.00 | -133,000.00 | -7,5% | |
| 2026-02-13 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -1,500 | 499.99 | -749,985.00 | -42,5% | |
| 2026-02-13 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -988 | 499.00 | -493,012.00 | -27,9% | |
| 2026-02-11 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -1,925 | 460.43 | -886,327.75 | -50,2% | |
| 2026-02-11 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -466 | 460.43 | -214,560.38 | -12,2% | |
| 2026-02-11 | Ambrose Kristen | Officer, SVP & Chief Accounting Officer | Open Market Sale | -1,376 | 460.43 | -633,551.68 | -35,9% | |
| 2026-02-11 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -1,751 | 460.43 | -806,212.93 | -45,7% | |
| 2026-02-11 | Bunnage Mark E. | Officer, EVP, Chief Scientific Officer | Open Market Sale | -2,021 | 460.43 | -930,529.03 | -52,7% | |
| 2026-01-07 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4,500 | 474.99 | -2,137,455.00 | -121,1% | |
| 2026-01-06 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -9,532 | 461.00 | -4,394,252.00 | -249,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1,320 | 441.26 | -582,463.20 | -33,0% | |
| 2025-12-03 | Tatsis Ourania | Officer, EVP, Chief Reg. & Quality Off. | Open Market Sale | -4,500 | 449.99 | -2,024,955.00 | -114,7% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -15,681 | 452.20 | -7,090,948.20 | -401,8% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -10,360 | 453.34 | -4,696,602.40 | -266,1% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -7,899 | 445.56 | -3,519,478.44 | -199,4% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5,880 | 449.84 | -2,645,059.20 | -149,9% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -5,809 | 451.20 | -2,621,020.80 | -148,5% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4,469 | 440.40 | -1,968,147.60 | -111,5% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -4,352 | 444.36 | -1,933,854.72 | -109,6% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2,469 | 443.21 | -1,094,285.49 | -62,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2,320 | 448.78 | -1,041,169.60 | -59,0% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -2,070 | 455.22 | -942,305.40 | -53,4% | |
| 2025-12-03 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1,152 | 447.05 | -515,001.60 | -29,2% | |
| 2025-12-03 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -347 | 449.00 | -155,803.00 | -8,8% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7,000 | 461.00 | -3,227,000.00 | -182,8% | |
| 2025-12-03 | WAGNER CHARLES F JR | Officer, EVP, CO & FO | Open Market Sale | -7,000 | 451.00 | -3,157,000.00 | -178,9% | |
| 2025-11-17 | Atkinson Edward Morrow III | Officer, EVP, Chief Technical Ops. Off. | Open Market Sale | -2,500 | 434.58 | -1,086,450.00 | -61,6% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -32,234 | 440.30 | -14,192,630.20 | -804,2% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -21,330 | 441.35 | -9,413,995.50 | -533,4% | |
| 2025-11-14 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -40 | 442.00 | -17,680.00 | -1,0% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -1,160 | 441.05 | -511,618.00 | -29,0% | |
| 2025-11-13 | LEIDEN JEFFREY M | Director, Officer, Executive Chairman | Open Market Sale | -18,528 | 440.22 | -8,156,396.16 | -462,2% | |
| 2025-10-02 | Biller Jonathan | Officer, EVP and Chief Legal Officer | Open Market Sale | -694 | 404.21 | -280,521.74 | -15,9% | |
| 2025-08-27 | Bhatia Sangeeta N. | Director | Open Market Sale | -266 | 386.69 | -102,859.54 | -5,8% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 4,290 | 389.08 | 1,669,153.20 | +94,6% | |
| 2025-08-06 | Kewalramani Reshma | Director, Officer, CEO & President | Open Market Purchase | 5,710 | 389.95 | 2,226,614.50 | +126,2% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 1,634 | 389.36 | 636,214.24 | +36,0% | |
| 2025-08-06 | SACHS BRUCE I | Director | Open Market Purchase | 3,366 | 389.84 | 1,312,201.44 | +74,4% | |
| 2025-05-15 | ALTSHULER DAVID | Officer, EVP, Chief Scientific Officer | Open Market Sale | -52 | 424.69 | -22,083.88 | -1,3% | |
| 2025-05-02 | Bhatia Sangeeta N. | Director | Open Market Sale | -400 | 505.86 | -202,344.00 | -11,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.